



Harnessing the Power of Naturally Occurring NK Cells to Fight Cancer


A large, detailed microscopic image of a cell, likely a Natural Killer (NK) cell, with a textured, bumpy surface. The image is rendered in shades of purple and blue. A white circular outline is superimposed on the right side of the cell, containing the company logo.

INDAPTA
THERAPEUTICS



Forward Looking Statement

This presentation contains forward-looking statements that are based on the company's current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry. The company makes no representations about the accuracy of such statements estimates or projections. Forward-looking statements are indicated by words such as: may, will, should, predict, continue, plan, expect, anticipate, estimate, intend, believe, could, goal objectives and similar expressions. Forward-looking statements may include, but are not limited to, statements concerning the company's anticipated performance, including revenue and profit expectations; development and implementation of collaborations; benefits provided to collaboration partners by our technology; business mix; revenues and growth in our partner base; market opportunities; competing technologies, industry conditions and trends; and regulatory developments. Actual results may differ materially from the anticipated results due to substantial risks and uncertainties related to the company and the biopharmaceutical industry in which the company operates.



INDAPTA

THERAPEUTICS

Off-the-shelf,
Best-in-Class
NK Cells

NK cell platform technology with clear differentiation


- Off-the-shelf, allogeneic cells “engineered by nature”
- ADCC activity markedly superior to conventional NK cells
- In vivo activity superior to published preclinical myeloma model NK cell benchmarks

Robust proprietary manufacturing process and cryopreservation method

Clinical trial initiation 1H 2023

Partnering opportunity

- Increase activity of IgG1 monoclonal Abs, ADCs or innate immune cell engagers
- Take clinically validated CAR-T constructs and engineer into off-the-shelf NK
- Extend patent life through generation of novel combination therapy IP



Our Team

Management

Mark Frohlich, MD

CEO

*Xcyte Therapies, Dendreon,
Juno, PACT, Neuvogen,
Bioeclipse*

Austin Bigley, PhD

VP, Research

Univ. Houston

Guy DiPierro

Founder | Chief Operating Officer

*AMGI Capital, Chrono
Therapeutics*

Robert Sikorski, MD PhD

Acting Chief Medical Officer

*Amgen , MedImmune, Five
Prime*

Board of Directors

Ronald Martell, Executive Chairman, Co-Founder

Mark Frohlich, CEO

Lori Hu, Vertex Ventures

Fabio Pucci, Leaps by Bayer

Laura Stoppel, RA Capital

Scientific Founders

Sungjin Kim, PhD | Scientific Founder

Associate Professor, UC Davis

John Sunwoo, MD | Scientific Founder,

Professor, Stanford University School of Medicine

Advisors

Todd A. Fehniger, MD/PhD | Professor of Medicine, Washington University

Nina Shah, MD | Professor of Clinical Medicine, UCSF

Vaughn Smider, MD, PhD | Associate Professor, Scripps Research Institute,

Catherine Polizzi | Chief IP Lawyer, Morrison Foerster, Palo Alto